Do I Qualify?

Make an Appointment

Content Hub


Find a Dispensary Read Articles


Applying for your medical marijuana card is easier than ever. Just book an appointment. Talk to a doctor. And get your card. Bing. Bam. Boom.

Marijuana Doctors

Get your medical marijuana card

Cannabis Consultation

One on one with a cannabis coach

Patient Login

Sign in to your Veriheal patient account


MI’s New Testing Policy, Utah’s First Union Dispo, & A $7.2B Psychedelic Forecast

Cesar Gallegos

by Cesar Gallegos

October 20, 2023 08:00 am ET Estimated Read Time: 3 Minutes

Here’s what you missed this week in cannabis and psychedelic news.

Michigan Ends Pre-Employment Drug Testing…Here’s The Catch

Earlier this month, Michigan officially ended pre-employment drug screenings for government employees. The Michigan Civil Service Commission unanimously approved the move over the summer. The policy change affects approximately 2/3 of state government jobs. However, individuals looking for law enforcement, healthcare, commercial driving, or jobs that handle dangerous materials are excluded from the policy.

Michigan’s decision to end pre-employment drug testing is motivated by the fact that the state already legalized recreational cannabis back in 2018. With cannabis completely legal to use, the state found it unfair to continue penalizing applicants for using it. Commissioner Nick Ciaramitaro further argued that the “Use of marijuana on the job is different than having used it months before you take the test.” 

The policy change only affects pre-employment drug screening. Michigan government employees will still be subject to random drug tests for designated positions.

But, what about the applicants who were turned away for positive drug tests? Michigan says that these individuals can go ahead and reapply! First, however, they’ll need to contact the Civil Service Department to request the removal of their past sanctions.

What do you think about Michigan’s latest move? Let us know in the comments!

Historic Victory: Utah’s First Cannabis Dispensary Unionizes!

Dragonfly Wellness Cannabis Dispensary (DWCD) in Utah has officially become the state’s first unionized dispensary! This marks the end of a long unionization fight that started when DWCD employees first started organizing back in July.

In August, DWCD employees connected with the United Food and Commercial Workers Union (UFCW). With the UFCW’s help, DWCD workers had enough momentum to schedule a vote. The final unionization vote happened in late September with workers voting 19-4 to join the UFCW. The vote represents the employees’ desire for fair treatment and recognition for their efforts within the industry.

Despite DWCD management’s best efforts to stop unionization, approximately 30 employees now have union protection. This includes wellness associates, drivers, pharmacists, and inventory specialists.

Utah is a medical-only state. Want to support the newly unionized DWCD employees? Make sure to get your medical card first.

Why You Should Get Your Medical Marijuana Card

Veriheal has satisfied millions of patients nationwide by giving them access to these benefits

  • Larger purchase limits
  • Peace of mind
  • Enhanced legal protection
  • Access to higher potency strains
  • Save up to 25% on cannabis purchases
  • Skip the line at the dispensary

GlobalData Report Predicts BIG Psychedelic Growth

A new report from GlobalData projected massive growth for the psychedelic industry in the next 6 years. According to the report, the psychedelic market is on track to reach a $7.2 billion valuation by the year 2029. The U.S.’s increasing support for the substances is one of the main drivers of this growth, the report says.

In June, the U.S. Food and Drug Administration (FDA) issued new guidelines supporting the research and development of psychedelic-based drugs. The FDA’s decision came in the midst of promising clinical trial results showing how psychedelics can help with various mental health disorders.

Three psychedelic drugs are projected to make up around 52% of the emerging market by 2029. The first, is PCN-101, a small-molecule drug for treatment-resistant depression. The second is CYB-003, a small molecule drug for major depressive disorder. The final, is SPL-026, another small molecule drug.

Do you agree with GlobalData’s report? Which psychedelics do you think will define the industry? Let us know in the comments!


View this post on Instagram


A post shared by Veriheal (@veriheal)

Visit Veriheal’s Content Hub for more cannabis news, lifestyle guides and the latest research.

Post Your Comments

Get your medical marijuana card today
Sign up in under 5 minutes